Project Grant 2008PMBX0016

This $1.4 million cooperative agreement from the Department of Justice Office of Justice Programs Bureau of Justice Assistance will support implementation of Missouri's first statewide prescription drug monitoring program under the Harold Rogers Prescription Drug Monitoring Program. The Joint Oversight Task Force for Prescription Drug Monitoring will utilize funding to train and educate prescribers and dispensers throughout the state on processes to submit data and comply with Missouri law. This...

The Department of Health and Human Services Agency for Healthcare Research and Quality awarded Oregon State University a $740,620 Project Grant under the Research on Healthcare Costs, Quality and Outcomes program (CFDA 93.226) to evaluate the integration of state prescription drug monitoring programs into electronic health records. Oregon Health & Science University and Comagine Health were named as sub-awardees to provide integration services for OHSU's Epic EHR system and support...

The Supreme Court of Ohio received a $962,064.75 cooperative agreement award from the Department of Justice Office of Justice Programs Bureau of Justice Assistance under the Harold Rogers Prescription Drug Monitoring Program. The award period is from October 1, 2017 through July 31, 2022 to enhance the capacity of regulatory and law enforcement agencies to collect and analyze controlled substance prescription data through the state's centralized prescription drug monitoring database, as outlined...

The National Institute on Drug Abuse awarded Labsys LLC $302,225 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable Continuous Polydrug Monitor (CPM) for substance use disorder treatment. The CPM is a wearable electrochemical sensor that continuously tracks fentanyl and other high-risk substances in interstitial fluid, using computationally designed anchor molecules for drug recognition, conductive polymers for signal amplification, and...

The National Institute on Drug Abuse awarded the University of Pittsburgh $945,601 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 30, 2025, for the Personalized Methadone Treatment (PROMOTE) study implementing shared decision making in opioid treatment programs. The project adapts implementation facilitation—a bundle of preparation, implementation, and sustainment strategies—to support systematic shared decision making (SDM) implementation within opioid treatment...

The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $409,750 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a secondary data analysis of national Medicaid claims examining variations in clinician responses to Prescription Drug Monitoring Program mandates. The recipient will analyze how emergency department, urgent care, and primary care clinicians adopt opioid prescribing regulations and policies differently,...

The National Institute on Drug Abuse awarded Boston Medical Center Corporation $2.67 million on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and implement LINK, a system-wide informatics intervention designed to optimize medications for opioid use disorder (MOUD) and pre-exposure prophylaxis for HIV (PrEP) utilization and reduce missed opportunities to prevent opioid overdose and HIV infection. LINK comprises two integrated components: LINK2CARE, a...

The National Institute on Drug Abuse awarded University of Wisconsin-Madison a $5.014 million cooperative agreement (UM1DA064515) on September 15, 2025, to conduct a three-arm comparative effectiveness cluster randomized controlled trial evaluating systems change approaches to scaling medications for opioid use disorder (MOUD) across 120 prisons in 12 states through May 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds implementation science research...

The National Institute on Drug Abuse awarded the University of Maryland, College Park $444,801 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to optimize medications for opioid use disorder (MOUD) expansion across Maryland using data-driven implementation strategies. The project constructs a MOUD access index integrating opioid use disorder prevalence, provider capacity, spatial accessibility, and contextual factors to model need for and access to MOUD....

The National Institute on Drug Abuse awarded the Board of Regents of Nevada System of Higher Education (University of Nevada, Reno) $402,205 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a research study examining medication for opioid use disorder (MOUD) access and treatment outcomes among individuals dually enrolled in Medicare and Medicaid. The research uses Medicare Advantage utilization and prescription claims data from 2021–2024 alongside...